Provided by Tiger Trade Technology Pte. Ltd.

Novartis AG

163.33
-0.5900-0.36%
Volume:1.26M
Turnover:204.27M
Market Cap:311.63B
PE:22.84
High:163.63
Open:162.70
Low:161.75
Close:163.92
52wk High:167.86
52wk Low:97.72
Shares:1.91B
Float Shares:1.82B
Volume Ratio:0.78
T/O Rate:0.07%
Dividend:4.00
Dividend Rate:2.45%
EPS(TTM):7.15
EPS(LYR):7.15
ROE:30.81%
ROA:11.14%
PB:6.76
PE(LYR):22.84

Loading ...

Novartis to Divest Majority Stake in Indian Subsidiary for $159 Million

Deep News
·
Yesterday

Trump Asserts Novartis Establishing Eleven Manufacturing Plants in the United States

Deep News
·
Yesterday

Unnatural Products in Pact With Novartis to Develop Macrocyclic Peptide Therapeutics

Dow Jones
·
Feb 18

U.S. RESEARCH ROUNDUP-Brixmor Property, Mohawk Industries, UDR

Reuters
·
Feb 17

Novartis on Track for Record High Closing -- Data Talk

Dow Jones
·
Feb 14

Novartis Says Vanrafia Late-Stage Data Support Slowing of Kidney Function Decline in IgA Nephropathy Patients

MT Newswires Live
·
Feb 13

Novartis price target raised to CHF 135 from CHF 125 at JPMorgan

TIPRANKS
·
Feb 13

Novartis’ treatment of progressive supranuclear palsy granted orphan designation

TIPRANKS
·
Feb 11

Correction to Super Bowl Ads Article on Feb. 6 and Feb. 7 -- WSJ

Dow Jones
·
Feb 11

Novartis downgraded to Hold from Buy at DZ Bank

TIPRANKS
·
Feb 10

Novartis breaks ground on biomedical research center in San Diego

TIPRANKS
·
Feb 07

Blood Tests and Better-for-You Soda: Super Bowl Ads May Be Healthiest Yet -- WSJ

Dow Jones
·
Feb 06

Novartis Submits Application in China for Groundbreaking Autoimmune Drug

Stock News
·
Feb 06

Novartis price target lowered to CHF 132 from CHF 133 at Citi

TIPRANKS
·
Feb 06

Novartis Faces Mounting ESG and Sustainability Risks That Could Weigh on Reputation, Financing, and Long-Term Value

TIPRANKS
·
Feb 05

Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead

Benzinga
·
Feb 05

Novartis reports Q4 core EPS $2.03 vs. $1.98 last year

TIPRANKS
·
Feb 04

Dow Jones Top Company Headlines at 7 AM ET: Wegovy Maker Novo Nordisk's Shares Slump After Guidance Disappoints | GE ...

Dow Jones
·
Feb 04

Novartis Forecasts Profitability Hit From Generic Drug Competition in U.S. -- Update

Dow Jones
·
Feb 04

Novartis 2026 Guidance a Bit Soft on Earnings -- Market Talk

Dow Jones
·
Feb 04